TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DAPTOMYCIN

DAPTOMYCIN
Infectious Disease Approved 2014-09-12
30
Indications
--
Phase 3 Trials
11
Years on Market

DAPTOMYCIN Approval History

Loading approval history...

What DAPTOMYCIN Treats

4 indications

DAPTOMYCIN is approved for 4 conditions since its original approval in 2014. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Skin and Skin Structure Infections
  • Staphylococcus Aureus Bloodstream Infections
  • Bacteremia
  • Infective Endocarditis
Source: FDA Label

Drugs Similar to DAPTOMYCIN

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

TYZAVAN
VANCOMYCIN HYDROCHLORIDE
2 shared
Hikma
Shared indications:
Infective EndocarditisSkin and Skin Structure Infections
ZEVTERA
CEFTOBIPROLE MEDOCARIL SODIUM
2 shared
ISTX
Shared indications:
BacteremiaInfective Endocarditis
AMPICILLIN AND SULBACTAM
AMPICILLIN SODIUM
1 shared
EUGIA PHARMA SPECLTS
Shared indications:
Skin and Skin Structure Infections
AVELOX
MOXIFLOXACIN HYDROCHLORIDE
1 shared
Bayer
Shared indications:
Skin and Skin Structure Infections
CEFAZOLIN AND DEXTROSE
CEFAZOLIN SODIUM
1 shared
B BRAUN
Shared indications:
Skin and Skin Structure Infections
CEFAZOLIN IN DEXTROSE
CEFAZOLIN SODIUM
1 shared
Baxter
Shared indications:
Skin and Skin Structure Infections
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER
CEFEPIME HYDROCHLORIDE
1 shared
B BRAUN
Shared indications:
Skin and Skin Structure Infections
CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE
1 shared
QILU ANTIBIOTICS
Shared indications:
Skin and Skin Structure Infections
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER
CEFEPIME HYDROCHLORIDE
1 shared
SAMSON MEDCL
Shared indications:
Skin and Skin Structure Infections
CEFEPIME IN PLASTIC CONTAINER
CEFEPIME HYDROCHLORIDE
1 shared
Baxter
Shared indications:
Skin and Skin Structure Infections
CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE
1 shared
UNIQUE
Shared indications:
Skin and Skin Structure Infections
CLARITHROMYCIN
CLARITHROMYCIN
1 shared
Teva
Shared indications:
Skin and Skin Structure Infections
CLEOCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE
1 shared
Pfizer
Shared indications:
Skin and Skin Structure Infections
DAPTOMYCIN IN 0.9% SODIUM CHLORIDE
DAPTOMYCIN
1 shared
Baxter
Shared indications:
Infective Endocarditis
ERTAPENEM SODIUM
ERTAPENEM SODIUM
1 shared
ACS DOBFAR SPA
Shared indications:
Skin and Skin Structure Infections
INVANZ
ERTAPENEM SODIUM
1 shared
Merck
Shared indications:
Skin and Skin Structure Infections
LINEZOLID
LINEZOLID
1 shared
SAGENT PHARMS INC
Shared indications:
Bacteremia
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
LINEZOLID
1 shared
Pfizer
Shared indications:
Bacteremia
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
MEROPENEM
1 shared
B BRAUN MEDICAL
Shared indications:
Skin and Skin Structure Infections
MOXIFLOXACIN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE
1 shared
Lupin
Shared indications:
Skin and Skin Structure Infections
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DAPTOMYCIN FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Daptomycin for injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) and, • Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, • Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). Limitations of Use : • Daptomycin for injection is not indicated for the treatment of pneumonia. • Daptomycin for injection is not indicated for the trea...

DAPTOMYCIN Patents & Exclusivity

Latest Patent: Aug 2038

Patents (16 active)

US12053502 Expires Aug 28, 2038
US11759497 Expires Aug 28, 2038
US10357535 Expires Sep 11, 2033
US9655946 Expires Sep 11, 2033
+ 6 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.